Posted on February 10th, 2016 by
Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively impacting both disease burden and quality of life. The identification of certain gene conditions that contribute to MPNs has led to improvements in diagnosis and stratifying risk. Ongoing trials will further define the role of JAK inhibitors in MPNs as well as evaluate combination therapies and new targeted therapies.
CancerConnect News coverage of advances in the management of MPNs included the following key developments:
Polycythemia Vera News
MPN Side Effect News
Click here for CURRENT MPN NEWS
Learning More About Myeloproliferative Neoplasms
Copyright © 2017 CancerConnect. All Rights Reserved.
You must be logged-in to the site to post a comment.